Trial Drug Could Clear Toxic Alzheimer’s Proteins and Restore Memory

Key Points:

• Researchers at Monash University found that the copper-based compound Cu(ATSM) reduced toxic amyloid-beta protein levels by 42% and improved long-term spatial memory by nearly 44% in laboratory models of Alzheimer's disease.
• Cu(ATSM) appears to restore the brain's blood-brain barrier function by increasing the number and activity of P-glycoprotein pumps, which help clear waste proteins from the brain into the bloodstream.
• The drug, previously tested for safety in neurological conditions like Parkinson's and ALS, could advance to human trials more quickly than other experimental Alzheimer's treatments due to its established safety profile.
• While promising, researchers are still investigating the exact mechanisms by which Cu(ATSM) enhances amyloid clearance, including potential effects on microglia immune cells, and emphasize the need for clinical trials to confirm cognitive and functional benefits in humans.
• The study highlights the importance of targeting vascular function and protein clearance in Alzheimer's therapy, suggesting that repairing the blood-brain barrier could slow or reverse disease progression.